Edition:
United States

United Therapeutics Corp (UTHR.OQ)

UTHR.OQ on NASDAQ Stock Exchange Global Select Market

117.34USD
10:50am EST
Change (% chg)

$6.37 (+5.74%)
Prev Close
$110.97
Open
$111.04
Day's High
$120.40
Day's Low
$110.50
Volume
51,744
Avg. Vol
152,077
52-wk High
$152.55
52-wk Low
$100.64

Latest Key Developments (Source: Significant Developments)

Arena Pharmaceuticals and United Therapeutics announce global license agreement for Ralinepag
7:00am EST 

Nov 15 (Reuters) - Arena Pharmaceuticals Inc ::ARENA PHARMACEUTICALS AND UNITED THERAPEUTICS ANNOUNCE GLOBAL LICENSE AGREEMENT FOR RALINEPAG.UNITED THERAPEUTICS - UNDER TERMS OF AGREEMENT, ARENA WILL GRANT CO EXCLUSIVE, WORLDWIDE RIGHTS TO DEVELOP, MANUFACTURE & COMMERCIALIZE RALINEPAG.UNITED THERAPEUTICS - ARENA WILL RECEIVE UP TO $1.2 BILLION, INCLUDING UPFRONT PAYMENT OF $800 MILLION & POTENTIAL MILESTONE PAYMENTS TOTALING UP TO $400 MILLION.UNITED THERAPEUTICS - ADDITIONALLY, ARENA WILL RECEIVE LOW DOUBLE-DIGIT TIERED ROYALTIES ON ANNUAL NET SALES OF RALINEPAG.  Full Article

United Therapeutics And Samumed Announce North American License Agreement For Samumed's IPF Drug Candidate
Monday, 17 Sep 2018 06:00am EDT 

Sept 17 (Reuters) - United Therapeutics Corp ::UNITED THERAPEUTICS - SAMUMED, CO ANNOUNCE NORTH AMERICAN LICENSE AGREEMENT FOR SAMUMED'S IPF DRUG CANDIDATE.UNITED THERAPEUTICS - DEAL TERMS INCLUDE $10 MILLION UP-FRONT, PLUS UP TO $340 MILLION IN DEVELOPMENTAL MILESTONES AND UP TO LOW DOUBLE-DIGIT ROYALTIES.UNITED THERAPEUTICS CORP - DEAL TERMS INCLUDE $10 MILLION UP-FRONT, PLUS UP TO $340 MILLION IN DEVELOPMENTAL MILESTONES AND UP TO LOW DOUBLE-DIGIT ROYALTIES.UNITED THERAPEUTICS - UNDER TERMS, UNIT OF CO WILL CONDUCT, FUND ALL FURTHER DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES IN U.S. & CANADA.UNITED THERAPEUTICS - SAMUMED RETAINS DEVELOPMENT AND COMMERCIALIZATION RIGHTS FOR ALL MARKETS OUTSIDE OF NORTH AMERICA.  Full Article

United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin
Friday, 30 Mar 2018 04:48pm EDT 

March 30 (Reuters) - United Therapeutics Corp ::UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING.  Full Article

United Therapeutics Corp Reports Qtrly EPS Of $0.43
Wednesday, 21 Feb 2018 06:00am EST 

Feb 21 (Reuters) - United Therapeutics Corp ::REPORTS 2017 FOURTH QUARTER AND ANNUAL FINANCIAL RESULTS.Q4 REVENUE $465 MILLION.QTRLY EARNINGS PER SHARE $0.43.QTRLY NON-GAAP EARNINGS PER SHARE $3.89.Q4 EARNINGS PER SHARE VIEW $3.89, REVENUE VIEW $421.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

United Therapeutics Settles Patent Litigation With Actavis Laboratories FL
Thursday, 15 Feb 2018 08:00pm EST 

Feb 15 (Reuters) - United Therapeutics Corp ::UNITED THERAPEUTICS ANNOUNCES SETTLEMENT OF PATENT LITIGATION WITH ACTAVIS LABORATORIES FL, INC. RELATING TO ORENITRAM.‍ENTERED INTO A SETTLEMENT AGREEMENT WITH ACTAVIS LABORATORIES FL, INC RESOLVING ONGOING LITIGATION​.‍UNDER SETTLEMENT AGREEMENT, CO GRANTED TO ACTAVIS LICENSE TO MANUFACTURE AND COMMERCIALIZE GENERIC VERSION OF ORENITRAM.SAYS PARTIES WILL ALSO TERMINATE PENDING LITIGATION CONCERNING PATENTS RELATING TO ACTAVIS' ANDA..UNITED THERAPEUTICS - ‍LICENSE IN SETTLEMENT AGREEMENT DOES NOT PERMIT ACTAVIS TO MANUFACTURE GENERIC VERSION OF ANY OTHER UNITED THERAPEUTICS PRODUCT​.‍ AGREEMENT DOES NOT GRANT ACTAVIS ANY RIGHTS OTHER THAN THOSE REQUIRED TO LAUNCH ACTAVIS' GENERIC VERSION OF ORENITRAM​.  Full Article

STEADYMED RECEIVES FAVORABLE RULING FROM U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT
Tuesday, 14 Nov 2017 09:56am EST 

Nov 14 (Reuters) - Steadymed Ltd ::‍COURT OF APPEALS AFFIRMED A MARCH 31 RULING BY PATENT TRIAL & APPEAL BOARD INVALIDATING U.S. PATENT NO 8,497,393 OWNED BY UNITED THERAPEUTICS​.‍INVALIDITY DECISION WILL PRECLUDE UNITED THERAPEUTICS FROM ASSERTING '393 PATENT PRIOR TO STEADYMED'S LAUNCH OF ITS TREVYENT PRODUCT​.‍FDA REGULATIONS REQUIRE THAT UNITED THERAPEUTICS "PROMPTLY NOTIFY FDA TO…WITHDRAW PATENT" FROM FDA'S "ORANGE BOOK."​.  Full Article

United Therapeutics Corp reports third quarter 2017 financial results
Wednesday, 25 Oct 2017 06:00am EDT 

Oct 25 (Reuters) - United Therapeutics Corp :United Therapeutics Corporation reports third quarter 2017 financial results.Q3 revenue $446 million versus I/B/E/S view $426.4 million.United Therapeutics Corp - qtrly ‍SHR $6.27​.United Therapeutics Corp - qtrly ‍non-GAAP earnings per diluted share $4.69​.Qtrly ‍non-GAAP earnings, per diluted share $4.69​.Q3 earnings per share view $3.87 -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system
Monday, 23 Oct 2017 06:00am EDT 

Oct 23 (Reuters) - United Therapeutics Corp :United Therapeutics announces FDA approval of third generation nebulizer for the Tyvaso inhalation system.United Therapeutics Corp - ‍launch of TD-300/A planned for mid-2018​.  Full Article

United Therapeutics Corp reports Q2 EPS non-GAAP $4.37
Thursday, 27 Jul 2017 06:00am EDT 

July 27 (Reuters) - United Therapeutics Corp ::United Therapeutics Corporation reports second quarter 2017 financial results.Q2 earnings per share non-GAAP $4.37.Q2 revenue $444.6 million, up 8pct.Q2 earnings per share view $3.61, revenue view $391.5 million -- Thomson Reuters I/B/E/S.  Full Article

United Therapeutics enters into agreement with Citibank relating to share repurchase program
Thursday, 1 Jun 2017 06:10am EDT 

June 1 (Reuters) - United Therapeutics Corp :United Therapeutics Corp - on May 31, 2017, co entered into agreement with Citibank, N.A. relating to a collared accelerated share repurchase program.United Therapeutics Corp says pursuant to terms of agreement, company will purchase $250 million of its common stock.United Therapeutics Corp says asr program is scheduled to be completed in Q4 of 2017.United Therapeutics Corp - on June 1, 2017, co expects to borrow $250 million aggregate principal amount under its revolving credit facility.United Therapeutics Corp says proceeds of revolving loans will be used to pay initial purchase price of its common stock to Citibank under asr program.  Full Article

Arena Pharma soars on deal with United Therapeutics for hypertension drug

Shares of Arena Pharmaceuticals Inc jumped nearly 30 percent after the drug developer sold rights to develop and sell its hypertension treatment to United Therapeutics Corp, fetching it $800 million in an upfront payment.